ABBREVIATIONS CI = confidence interval; DIND = delayed ischemic neurological deficit; GCS = Glasgow Coma Scale; GOS = Glasgow Outcome Scale; HDS-SAH = High-Dose Simvastatin for Aneurysmal Subarachnoid Hemorrhage; HHH = hypertension, hypervolemia, and hemodilution; M-H = Mantel-Haenszel; mRS = modified Rankin Scale; RCT = randomized controlled trial; RR = relative risk; SAH = subarachnoid hemorrhage; STASH = Simvastatin in Aneurysmal Subarachnoid Hemorrhage; TCD = transcranial Doppler; WFNS = World Federation of Neurosurgical Societies. 
findings. 5, 10, 18, 37, 42, 44 Meta-analyses have also produced inconsistent results. Four studies demonstrated a beneficial effect of statin treatment in at least 1 aspect, 33, 34, 36, 48 while no benefits were reported by the authors of 3 additional studies. 16, 17, 41 Recently, 2 large-scale multicenter Phase III trials-Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) and High-Dose Simvastatin for Aneurysmal Subarachnoid Hemorrhage (HDS-SAH)-yielded disappointing findings; no benefits of simvastatin treatment were observed in patients with aneurysmal SAH during the STASH study, while authors of the HDS-SAH study reported that treatment with high doses of simvastatin (80 mg) was no more effective than treatment with low doses (40 mg). 13, 44, 47 Both studies had limitations; no details of vasospasm were described in the STASH study, and no control group was used in the HDS-SAH study, making it difficult to draw firm conclusions. 17 Therefore, the effect of statins on vasospasm remains unclear; positive effects may have been neutralized through an adverse pathway. Alternatively, statins may not be effective in humans. These questions currently remain unanswered.
Recently, a prospective cohort trial was published that investigated cognitive outcome after acute simvastatin treatment. 45 The observation period was not longer than 3 months; therefore, this type of study, with matched baseline characteristics and no loss to follow-up, may prove more useful than some small-scale randomized controlled trials (RCTs). A large-scale meta-analysis including RCTs and prospective cohort studies might reveal better evidence of the medical efficacy of statins in treating patients with aneurysmal SAH.
Methods

Search Strategy
We performed a literature search of the PubMed, Ovid, and Cochrane Library databases in November 2015. Additionally, we screened the US NIH clinicaltrials.gov database to identify ongoing clinical trials. The following search terms were used: 1) "statin" and "statin*" and "$statin"; 2) "aneurysmal subarachnoid hemorrhage" and "subarachnoid h*emorrhage" and "subarachnoid hemorrhage." We restricted the search to human studies, without any language limitations. All search results, including review articles, were evaluated by 2 investigators (J.W.P. and H.J.). Finally, the authors of the studies included in this meta-analysis were contacted to obtain any unpublished data related to the subject of our analysis.
Two investigators (J.W.P. and H.J.) independently selected potentially appropriate trials from the retrieved literature according to our inclusion criteria. The initial selection was based on a review of the title and abstract, and in a second selection the investigators reviewed the text in full. A consensus on which studies to include was established after a discussion between the investigators.
Eligibility Criteria
The following inclusion criteria were applied: 1) RCTs or prospective cohort studies investigated the effects of acute statin therapy in treating SAH; 2) patients were all diagnosed with aneurysmal SAH; 3) studies included at least 1 of the following end points: cerebral vasospasm, DIND, delayed cerebral ischemia, outcomes measurements, and mortality.
The following exclusion criteria were applied: 1) the efficacy of statin treatment not investigated in human participants (such as experimental investigation and animal studies); 2) unmatched patient baseline characteristics between groups; 3) statin treatment of SAH not caused by ruptured aneurysm (such as trauma and arteriovenous malformation rupture); 4) statin treatment investigated prior to SAH or investigation into long-term use of statins; and 5) comparison of statin treatment with other drugs (such as magnesium sulfate and nimodipine).
Data Extraction
Data were extracted independently by 2 investigators (J.W.P. and H.J.), and a consensus was established. The following information was extracted from each publication: journal name, year of publication, first author, demographic information, baseline demographic and clinical characteristics, inclusion and exclusion criteria, interventions, and number of end points per subgroup. No unpublished data were received from the authors of the included studies.
Study End Points
The primary end point was cerebral vasospasm, and the secondary end points included DIND, delayed cerebral infarction, favorable outcomes, and mortality. The end points were defined according to the original studies (Table 1) .
Statistical Analysis
Relative risks (RRs) and 95% confidence intervals (CIs) were calculated from the number of outcome events per subgroup to estimate the association of statin administration with various end point events. The heterogeneity of the study results was assessed by Cochran c 2 Q statistics and the I 2 test, which determined whether the fixed-effects Mantel-Haenszel (M-H) or random-effects DerSimonian and Laird model was used. A p value ≤ 0.1 or I 2 value ≥ 50% was considered indicative of heterogeneity. Sensitivity analyses were conducted to assess the influence of specific studies on the combined effect. All tests were 2-sided, and a p value ≤ 0.05 was considered significant. Statistical analyses were performed with Review Manager 5.3 and the Stata statistical software package (release 14.0; Stata Corp.).
Methodological Quality Assessment
Two investigators (J.W.P. and Y.X.W.) independently evaluated the methodological quality of the included trials with the Cochrane Collaboration's tool for assessing risk of bias, and a consensus was established.
Results
Search Results
One hundred sixteen studies were retrieved from PubMed, 57 from Ovid, 72 from the Cochrane Library, and 8 clinical trials were retrieved from the clinicaltrials. gov database. Duplicate studies and studies that did not meet the inclusion criteria were excluded. Two RCTs were excluded based on unmatched baseline patient characteristics: 1) Vergouwen et al. 2009 , in which there were 44% of patients (7/16) in the simvastatin group and 6% of patients (1/16) in the placebo group, with a World Federation of Neurosurgical Societies (WFNS) score ≥ 4 (p = 0.00, Fisher's exact test); and 2) Diringer et al. 2014, in which there were 13% of patients in the simvastatin group and 42% of patients in the placebo group, with a WFNS score of 3-5.
7,42 Six RCTs and 2 prospective studies qualified for the meta-analysis. 5, 10, 13, 18, 21, 23, 37, 45 A flowchart of the literature search for eligible articles is shown in Fig. 1 .
Characteristics of Eligible Studies
The characteristics of the included studies are listed in Table 1 . The eligibility criteria for patients recruited were similar between the trials. A total of 1461 patients were included: 1019 patients from 6 RCTs and 442 patients from 2 prospective studies. 5, 10, 13, 18, 21, 37, 42, 45 Four hundred ninety-nine patients received statin treatment and 520 patients received placebo treatment in 6 RCTs. Two hundred twenty-one patients received statin treatment and 221 patients received placebo treatment in 2 prospective studies. Baseline characteristics were described in detail, except in 1 study. 21 Seventy percent of the patients were female (1004/1441). WFNS or Hunt and Hess grades were described in all studies except 2.
18,21 Twenty-two percent of patients (311/1402) were in an initial comatose state (WFNS Grade ≥ 4). The Fisher grade was provided in 6 studies, and 43% of patients (541/1252) were Fisher Grade IV. 5, 10, 13, 18, 21, 23 Management of ruptured aneurysms was described in all except 1 study, and 49% of patients (713/1441) underwent microsurgical clipping. 21 Patient characteristics with a potential effect on the outcomes were similar between the simvastatin and placebo groups. Details of administered treatments, including nimodipine and fluid therapy, were described in all studies.
Definitions of Study End Points
Definitions and results of the study end points are presented in Table 2 . Vasospasm was defined in multiple ways in some studies; we analyzed the transcranial Doppler (TCD) cerebral artery velocity in this meta-analysis. Four studies used TCD cerebral artery velocity to detect vasospasm, and these velocities varied. 5, 10, 18, 37 In the studies by McGirt et al. and Macedo et al., vasospasm was defined as responding to the combination of induced hypertension, hypervolemia, and hemodilution (HHH) therapy, or angiographic change. 21, 23 Definitions of the secondary end points also varied; new ischemic neurological deficits or a decrease in 2 or more points on the modified Glasgow Coma Scale (GCS) were the criteria of DIND in 5 studies.
5,10,13,37,45 Delayed cerebral infarction was mainly confirmed by CT, MRI, or other radiological strategies in 4 studies. 5, 13, 37, 44 Mortality rates were provided in 6 studies, and the Glasgow Outcome Scale (GOS) and modified Rankin Scale (mRS) scores were assessed in 7 studies. 5, 10, 13, 21, 22, 37, 45 The time of assessment ranged from hospital discharge to 3-6 months after the ictus. In 2 RCTs, only the median GOS and mRS scores were provided, without the exact patient values for each score. 10, 21 A favorable outcome was defined as an mRS score ≤ 2 in 4 studies and a GOS score ≥ 3 in 1 study. 5, 13, 23, 37, 45 
Risk of Bias Assessment
The quality of the included studies was measured by Cochrane risk of bias assessment. If bias was not addressed in the trials, we assumed an unclear risk. The 2 prospective studies showed a high risk for randomization and blinding, while 2 of the small-sample RCTs showed unclear bias risk by failing to describe the WFNS grade. However, these conclusions are subjective (Fig. 2) .
Outcomes of Meta-Analysis
The pooled results are shown in Fig. 3 . The incidence of cerebral vasospasm was 29% (82/278) and 39% (108/278) in statin-treated and placebo-treated patients, respectively. The statin-treated group had a lower incidence of cerebral vasospasm (M-H pooled RR 0.76, 95% CI 0.61-0.96; p = 0.02). Analysis of heterogeneity revealed mild heterogeneity among the studies (heterogeneity c 2 = 8.55, I 2 = 42%, p = 0.13). Sensitivity analysis revealed that 1 RCT was mainly responsible for the heterogeneity (omitted heterogeneity c 2 = 3.26, I 2 = 0%, p = 0.46), which may be explained by the alternative definition of a vasospasm DIND was observed in 19% (98/520) of statin-treated patients and 21% (115/542) of placebo-treated patients, with no statistically significant difference between the 2 groups (M-H pooled RR 0.88, 95% CI 0.70-1.12, p = 0.31). The heterogeneity of DIND was mild (heterogeneity c 2 = 7.45, I 2 = 46%, p = 0.11). Sensitivity analysis revealed that heterogeneity of DIND was significantly reduced by eliminating the pravastatin study (omitted heterogeneity c 2 = 1.75, I 2 = 0%, p = 0.63), while the RR was not significantly affected (omitted M-H pooled RR 0.97, 95% CI 0.76-1.24, p = 0.80). 37 Delayed cerebral infarction did not differ significantly between statin-treated and placebo-treated patients (statintreated 15% [73/501], placebo-treated 18% [95/523], M-H pooled RR 0.66, 95% CI 0.33-1.31, p = 0.24). There was moderate heterogeneity in the occurrence of delayed cerebral infarction among the studies (heterogeneity c 2 = 6.44, I 2 = 53%, p = 0.09), and sensitivity analysis showed that the pravastatin study significantly enhanced heterogeneity (omitted heterogeneity c 2 = 1.22, I 2 = 0%, p = 0.54), while the RR was not affected (omitted M-H pooled RR 0.90, 95% CI 0.67-1.20, p = 0.46). 37 Favorable outcome was measured by mRS score in 4 studies and by GOS score in 1 study. 5, 13, 23, 37, 45 There was no significant difference in the number of patients with 22) , and no heterogeneity in the mortality rate was observed between the studies (heterogeneity c 2 = 10.36, I 2 = 52%, p = 0.07). Sensitivity analysis revealed that the RR estimate and heterogeneity were not affected by the exclusion of any study (Table 3) .
Meta-Analysis of Subgroups
We included 2 prospective cohort studies and 6 RCTs, which may have enhanced the potential clinical heterogeneity. 23, 45 One RCT used pravastatin (a hydrophilic statin) while the others used simvastatin (a lipophilic statin). Additionally, to measure patient outcome, some studies used mRS score while others used GOS score. To address this heterogeneity, we conducted subgroup meta-analyses (Table 4).
There was moderate heterogeneity in vasospasm analysis among the RCTs (heterogeneity c 2 = 8.72, I 2 = 54%, p = 0.07), which was not significant according to the random method (random M-H pooled RR 0.70, 95% CI 0.42-1.18; p = 0.18) on a small-scale analysis of 216 patients. 5, 10, 18, 21, 37 The occurrence of DIND, delayed cerebral infarction, favorable outcome, and death were not significantly different between RCTs and prospective cohort studies. The incidence of cerebral vasospasm was not significantly altered by simvastatin treatment (random M-H pooled RR 0.77, 95% CI 0.48-1.23, p = 0.27), and the level of heterogeneity was moderate (heterogeneity c 2 = 7.97, I 2 = 50%, p = 0.09). 5, 10, 13, 18, 21, 23 No significant difference was observed in the incidence of other outcomes in the simvastatin-treated subgroup analysis. Pravastatin treatment appears to reduce the incidence of DIND and delayed cerebral infarction according to the study by Tseng et al. 37 Omission of this study reduced the heterogeneity of the DIND and delayed cerebral infarction analysis. A similar effect was observed on the favorable outcomes measured by the mRS and GOS.
Discussion
The ongoing publication of new clinical trials and different eligibility criteria can make the results from previous meta-analyses controversial. Most previous metaanalyses have only included RCTs with a small number of patients (≤ 40), which were likely to have mismatched patient characteristics between the statin-treated and control groups. This represents a potential source of bias for previous meta-analyses. The patients' baseline characteristics should be carefully considered, especially when evaluating characteristics that have a great impact on the clinical end points. To our knowledge, patients with aneurysmal SAH and a high WFNS grade (4-5) have a higher incidence of DIND compared with patients with low WFNS grades.
6,30 Hence, we only included studies with similar WFNS grades in the statin-treated and placebo-treated groups and excluded those studies with mismatched clinical characteristics between groups. Two recently published, large-scale multicenter randomized Phase III trials (STASH and HDS-SAH) have not investigated the relationship between statin treatment and vasospasm. The authors of the HDS-SAH study have recently published another prospective cohort trial that investigated the cognitive outcome following acute simvastatin treatment. 45 In our opinion, studies with matched baseline characteristics between the groups are preferable to RCTs if they had no loss to follow-up because of a short-term observation period (≤ 3 months). We excluded the retrospective cohort studies from our analysis because they had a larger bias than prospective studies and the study design, population, intervention, and control were variable. 17 We included 6 RCTs and 2 prospective cohort studies that met our eligibility criteria, to generate a larger scale meta-analysis, and obtain a more accurate conclusion.
Our meta-analysis was also the first to analyze cerebral infarction as an end point, which is difficult to distinguish from severe DIND, especially in comatose or sedated patients. 26, 43 DIND can either be reversible or progress to delayed cerebral infarction, which is often confirmed by an infarction lesion on CT or MRI scan within 6 weeks after SAH. This is a common cause of unfavorable outcome and death. 26 After a series of analyses, we found that patients with aneurysmal SAH in the statin-treated groups have a significantly lower incidence of vasospasm. This finding is contradictory to 5 previous meta-studies and consistent with 2 meta-analyses previously published. 16, 17, 33, 34, 36, 41, 48 The results regarding the secondary outcomes were disappointing. We found no evidence that statin treatment can improve DIND or delayed cerebral infarction. We also confirmed that there is no long-term benefit of statin treatment, evaluated by the mRS or GOS.
Previously published meta-analyses are summarized in Table 5 . Compared with previous meta-analyses, our study has included the STASH study and imposed stricter eligibility criteria than other reviews, making our results more credible. Additionally, the present study has analyzed a larger number of patients in the meta-analysis (especially of vasospasm) and has a lower heterogeneity and higher power than those previously published. The clustering of all end point results in our study is also a novel finding compared with previous meta-analyses of the same subject.
The reduction in vasospasm did not translate into a measurable clinical benefit according to our analysis. This finding is supported by a recent prospective study comparing the efficacy of different simvastatin doses on cerebral vasospasm. 46 This finding is very similar to that seen in the studies of clazosentan (the Clazosentan to Overcome Neurological Ischemia and Infarct Occurring After Subarachnoid Hemorrhage [CONSCIOUS] trials), in which vasospasm improvement occurs but functional outcome was not improved and mortality rate was not reduced. 20, 31, 38, 47 Vasospasm is not the only cause of DIND. Regional hypoperfusion and oligemia frequently occurred in territory or patients without angiographic vasospasm, and other factors such as early brain injury, cortical spreading depression ischemia, cerebral autoregulatory failure, and microthrombosis have been reported to cause DIND. 3, 9, 19, 27, 30 Taken together, these findings support a relationship between vasospasm and DIND and show that clinical deterioration due to DIND is more than simply angiographic vasospasm, and our findings support this. 29 Further research should focus on DIND and delayed cerebral infarction. 27 The failure of statin treatment may be attributed to an aggravation of other risk factors, despite its pharmacological efficacy in treating vasospasm. For example, some studies have shown that statins may increase the risk of intracerebral hemorrhage and hemorrhagic stroke by lowering the cholesterol level. 2, 11 It remains to be investigated whether the effectiveness of statin treatment can be improved in combination with other therapies, such as HHH therapy to reduce cerebral autoregulatory failure. 15 The pathophysiological mechanism of these ischemic deficits and the possible relationship between statins and other etiologies of DIND remain to be elucidated.
There are several potential limitations to our metaanalysis. First, the included studies were not all RCTs, which may have enhanced the methodological heterogeneity. However, there are not enough published studies assessing DIND and delayed cerebral infarction to avoid heterogeneity altogether. Finally, substantial differences in the study design among RCTs, including differences in the treatment and outcome evaluation, were unavoidable, which may account for the heterogeneity between RCTs according to the subgroup analysis.
Conclusions
Statin treatment significantly reduced vasospasm but failed to reduce DIND, delayed cerebral infarction, or mortality rate. The outcome following aneurysmal SAH was also not improved by statin treatment. Further research should focus on DIND rather than simply on angiographic vasospasm and how statins influence DIND.
